The United Laboratories International Holdings Limited (DE:UNJ)
FRANKFURT:UNJ
UNJ Stock Chart & Stats
€1.47
-€0.01(-0.75%)
At close: 4:00 PM EST
€1.47
-€0.01(-0.75%)
Day’s Range― - ―
52-Week Range€0.90 - €1.87
Previous CloseN/A
Volume0.00
Average Volume (3M)42.00
Market Cap
€1.83B
Enterprise Value€8.75B
Total Cash (Recent Filing)€11.24B
Total Debt (Recent Filing)€4.99B
Price to Earnings (P/E)7.1
Beta0.69
Next Earnings
Aug 27, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.14
Shares Outstanding1,973,026,500
10 Day Avg. Volume100
30 Day Avg. Volume42
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)1.13
Price to Sales (P/S)1.49
P/FCF Ratio22.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.74Price Target Upside18.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.07
Revenue Forecast (FY)€1.42B
Bulls Say, Bears Say
Bulls Say
Sustained Gross MarginsA gross margin around 42% indicates enduring product-level profitability and pricing power typical of established pharmaceutical producers. This margin buffer supports reinvestment in R&D and absorbs input-cost swings, sustaining core earnings even if topline growth slows.
Conservative Leverage ProfileLow to moderate leverage provides financial flexibility to fund R&D, manufacturing scale-up or M&A without immediate refinancing pressure. A conservatively levered balance sheet improves resilience through industry cycles and supports longer-term strategic investments.
Established Scale And Prior Revenue ExpansionMulti-year top-line expansion and asset growth reflect successful product commercialization and distribution capability. Scale supports cost efficiencies, channel access and competitive positioning that can underpin recovery and sustainable earnings over the medium term.
Bears Say
Recent Topline DeclineAn almost 9% revenue drop in 2025 signals weakening demand or market share loss, reducing growth runway. If structural (product life cycles, competitive pressure or pricing), this decline can persist beyond a quarter and constrain reinvestment and long-term growth prospects.
Falling Return On EquityA sharp ROE decline implies diminishing effectiveness of capital deployment—driven by lower margins or earnings—reducing shareholder returns and potentially necessitating strategic changes. Persistently lower ROE weakens the case for aggressive capital allocation.
Weak, Volatile Cash ConversionLow and volatile free cash flow relative to net income undermines earnings quality and limits internal funding for capex, R&D and dividends. Persistent cash conversion weakness increases reliance on external financing and reduces resilience to prolonged revenue weakness.
The United Laboratories International Holdings News
UNJ FAQ
What was The United Laboratories International Holdings Limited’s price range in the past 12 months?
The United Laboratories International Holdings Limited lowest stock price was €0.90 and its highest was €1.87 in the past 12 months.
What is The United Laboratories International Holdings Limited’s market cap?
The United Laboratories International Holdings Limited’s market cap is €1.83B.
When is The United Laboratories International Holdings Limited’s upcoming earnings report date?
The United Laboratories International Holdings Limited’s upcoming earnings report date is Aug 27, 2026 which is in 74 days.
How were The United Laboratories International Holdings Limited’s earnings last quarter?
The United Laboratories International Holdings Limited released its earnings results on Mar 24, 2026. The company reported €0.014 earnings per share for the quarter, beating the consensus estimate of €0.008 by €0.006.
Is The United Laboratories International Holdings Limited overvalued?
According to Wall Street analysts The United Laboratories International Holdings Limited’s price is currently Undervalued.
Does The United Laboratories International Holdings Limited pay dividends?
The United Laboratories International Holdings Limited does not currently pay dividends.
What is The United Laboratories International Holdings Limited’s EPS estimate?
The United Laboratories International Holdings Limited’s EPS estimate is 0.05.
How many shares outstanding does The United Laboratories International Holdings Limited have?
The United Laboratories International Holdings Limited has 1,973,026,500 shares outstanding.
What happened to The United Laboratories International Holdings Limited’s price movement after its last earnings report?
The United Laboratories International Holdings Limited reported an EPS of €0.014 in its last earnings report, beating expectations of €0.008. Following the earnings report the stock price went up 1.835%.
Which hedge fund is a major shareholder of The United Laboratories International Holdings Limited?
Currently, no hedge funds are holding shares in DE:UNJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
The United Laboratories International Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€1.74 (18.15% Upside)
€1.74 (18.15% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.89%
12-Months-Change
Fundamentals
Return on Equity
12.65%
Trailing 12-Months
Asset Growth
24.94%
Trailing 12-Months
Company Description
The United Laboratories International Holdings Limited
The United Laboratories International Holdings Limited functions as an investment holding company with a primary focus on the pharmaceutical sector. Its multifaceted operations cover the entire lifecycle of drug development and commercialization, from pioneering research and development to manufacturing, distribution, and sales. The company structures its diverse business into three core divisions: Bulk Medicine, Intermediate Products, and Finished Goods. Its broad product portfolio features a variety of medications, such as oral antibiotics, injectable antimicrobials, cold and cough remedies, ophthalmic solutions, antiviral and anti-hepatitis B drugs, diabetes treatments, topical dermatological preparations, cardiovascular and neurological pharmaceuticals, vitamins, and empty gelatin capsules, alongside active pharmaceutical ingredients (APIs) and other intermediary compounds. Furthermore, the company manufactures and markets soft capsule shells, holds trademarks, engages in pharmaceutical trading, and provides management services. Founded in 1990 and headquartered in Yuen Long, Hong Kong, the firm maintains a significant global reach, conducting business throughout the People's Republic of China, Europe, India, the Middle East, South America, other Asian territories, and internationally.
UNJ Stock 12 Month Forecast
Average Price Target
€1.74
▲(18.15% Upside)
Technical Analysis
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Consun Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---